Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Askel Healthcare to Present First Clinical Trial Results of Its COPLA® Knee Cartilage Implant at the 9th Joint Preservation Congress in Warsaw, Poland on June 14-15, 2024


News provided by

Askel Healthcare Oy

14 Jun, 2024, 06:13 GMT

Share this article

Share toX

Share this article

Share toX

HELSINKI, June 14, 2024 /PRNewswire/ -- Askel Healthcare, a Finnish medical technology company pioneering the treatment and repair of focal knee cartilage defects, will present results from its first-in-human Pilot Clinical Trial at the 9th Joint Preservation Congress in Warsaw on June 14-15. The primary endpoint of the trial, safety, was successfully met in all initial ten patients. The trial also provided promising preliminary efficacy data.

The COPLA® Cartilage implant is a novel biodegradable solution designed to surgically treat knee cartilage damage. Askel Healthcare aims for this implant to become the global standard for first-line surgical knee cartilage repair. A key differentiator of the COPLA® Cartilage implant is its ability to allow immediate, unrestricted full weight-bearing post-surgery. This facilitates faster rehabilitation and a quicker return to activities, as were observed in the Pilot Trial. Early mechanical loading aids cartilage regeneration, contributing to the formation of high-quality tissue, and is essential for long-term positive outcomes.

Key Findings from the Pilot Trial Based on the Interim Report with the first 10 Subjects at the 6-Month Follow-Up:

  • Safety: COPLA® Cartilage implant is safe for use in humans with no implant-related complications reported.
  • Weight-Bearing: All patients achieved full and unrestricted weight-bearing immediately after surgery and maintained this ability throughout the first six months.
  • Clinical Improvements: Significant improvements in knee function and pain levels were observed over six months, with no pain medication needed from six weeks post-surgery onwards.
  • Recovery: Physiotherapist evaluations indicated good recovery, with knee movement improved and strength returning to pre-surgery levels within three months. All patients returned to their pre-injury activity levels between six weeks and three months, which was maintained at six months. Patients reported high satisfaction with the surgery, noting an overall improvement in their quality of life.
  • Ease of use: The implantation of COPLA® was successful in all surgeries. Tailoring and placement of the implant to the lesion, added on average 15 minutes to the length of surgery. No special instrumentation was needed.

"Cartilage defects are prevalent, particularly among athletes, and existing treatments are often unreliable. The initial results with COPLA® are impressive, showing promise for active patients by enabling early weight-bearing, swift rehabilitation, and a quick return to activities. However, it is important to note that these outcomes are based on a very small patient sample." stated Dr. Teemu Paatela (MD), Chief Orthopaedic Surgeon and Director of Musculoskeletal Businesses at Terveystalo, Finland's largest private hospital chain. Dr. Paatela is the Coordinating Principal Investigator in the ongoing COPLA® Pilot Clinical Trial and a member of Askel's Clinical Advisory Board. He will present the Pilot Trial results at the Warsaw Joint Preservation Congress, which focuses on joint preservation and explores topics related to orthobiology, regenerative medicine, and innovative techniques in orthopedics, bringing together experts and researchers in these fields.

"One of the most rewarding aspects of the Pilot Trial were the comments we received from the patients implanted with COPLA®. Knee pain and movement limitations are very disabling for anyone, but even more for the physically active individuals who were the majority of the population in the Pilot Trial. Hearing their stories about returning to the sports or activities they love without pain or discomfort has been very rewarding." commented Petra Raatikka, Chief Clinical Officer at Askel Healthcare.

Askel's strategy involves collaboration with globally renowned orthopedic surgeons and sports medicine specialists in its clinical development. The company has established a prestigious Clinical Advisory Board (CAB) comprising internationally recognized experts in cartilage damage treatment. The CAB is chaired by Swedish professor Mats Brittberg (MD), an orthopedic surgeon and honorary member of the International Cartilage Regeneration and Joint Preservation Society (ICRS), and a leading researcher in knee cartilage repair.

In addition to Prof. Brittberg and Dr. Paatela, other esteemed members of Askel Healthcare's CAB include:

  • Dr. Emmanuel Papakostas (MD): Member of ICRS and consultant orthopedic surgeon at Aspetar Orthopaedic and Sports Medicine Hospital in Doha, Qatar. Dr. Papakostas has served as head team physician for professional football clubs and continues as a consultant surgeon for several clubs and national associations. He has been actively involved in the 2004 Athens and 2008 Beijing Olympics and the 2022 FIFA World Cup in Doha.
  • Mr. Konstantinos Epameinontidis: Senior Physiotherapist at Aspetar Hospital, specializing in knee injury rehabilitation. He has published several research articles on knee injury rehabilitation.

The company will now turn its focus towards an upcoming Pivotal Trial, for which preparations are well underway. Meanwhile, the Pilot Trial will continue to be closely monitored, with key milestones including the one-year results from the first ten patients expected by the end of this year, followed by the 12- and 24-month results from all 20 patients. The Pivotal Trial will aim to demonstrate the clinical benefits of COPLA® in a randomized trial that is designed to show superiority over current surgical standard treatments and will serve as a cornerstone for market authorizations in the US and EU. Patient recruitment is scheduled to begin in the first half of 2025, and Askel has appointed Dr. Konrad Slynarski (MD) as the Coordinating Principal Investigator. Dr. Slynarski is a distinguished member of the International Cartilage Regeneration and Joint Preservation Society (ICRS) as well as several other sports medicine and orthopedic societies. He is also a member of the Organizing and Scientific Committees for the Joint Preservation Congress in Warsaw.

The company announced the issuance of its first patent for COPLA® technology in April this year. The patent was validated as a Unitary Patent, which covers 17 EU-countries. In addition to this, the company has also extended its patent coverage to key markets including the United Kingdom, Spain, and Switzerland. This comprehensive approach ensures that Askel Healthcare's innovative technology is safeguarded in a total of 20 countries in Europe, laying a solid foundation for international growth and market penetration.

Additional information:

Askel Healthcare, Chief Clinical Officer, Petra Raatikka. Tel. +358 40 354 8482

Coordinating Investigator, MD, Teemu Paatela. Tel. +358 40 586 4429

About Askel Healthcare

Askel Healthcare is a Finnish medical technology company set to transform surgical knee cartilage treatment and recovery. Our mission is to keep people in motion through our universal COPLA® Cartilage implant, which is a ground-breaking innovation for the repair of knee cartilage defects. For more information, visit: www.askelhealthcare.com and https://youtu.be/RSZwLWwfwe8.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/askel-healthcare-oy/r/askel-healthcare-to-present-first-clinical-trial-results-of-its-copla--knee-cartilage-implant-at-the,c4000229

The following files are available for download:

https://mb.cision.com/Main/22234/4000229/2862257.pdf

Press release (PDF)

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.